Delivering Unprecedented Access to Biosimilars in Global Markets
  • Developing, Manufacturing and Commercializing
    Biosimilar Products for Global Markets
Who We Are

Epirus is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. Epirus’s strategy addresses the fragmented and complex global regulatory and commercial landscape for biosimilars and leverages market insights with close local collaborations to gain competitive advantages in target markets.

Learn More

News & Events

September 25, 2014

EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China

September 23, 2014

EPIRUS Announces Positive 58 Week Follow Up Data for BOW015 for treatment of Rheumatoid Arthritis

Bookmark and Share